Sugi Predict

Sugi Predict / Compounds / SCHEMBL1381808

SCHEMBL1381808

SCHEMBL1381808

C=CC(=O)Nc1ccc(C(C)C)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 10/20 0.65
▸ F13A1 P00488 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ TGM1 P22735 1/20 0.59
▸ TGM3 Q08188 1/20 0.59
▸ EGFR P00533 1/20 0.58
▸ FYN P06241 1/20 0.56
▸ SRC P12931 1/20 0.56
▸ KIF11 P52732 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ HPGD P15428 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ THRA P10827 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20885056 0.89 TGM2 (0.63) TGM2F13A1LMNATGM1TGM3
SCHEMBL2722982 0.86 TGM2 (0.61) TGM2F13A1LMNATGM1TGM3
SCHEMBL2723385 0.86 TGM2 (0.61) TGM2F13A1LMNATGM1TGM3
SCHEMBL38661653 0.86 TGM2 (0.61) TGM2F13A1LMNATGM1TGM3
SCHEMBL23328326 0.86 TGM2 (0.61) TGM2F13A1LMNATGM1TGM3
SCHEMBL23988634 0.85 TGM2 (0.58) TGM2F13A1LMNATGM1SMN1; SMN2
SCHEMBL439369 0.84 TGM2 (0.79) TGM2F13A1LMNATGM1TGM3
SCHEMBL10033524 0.83 TSHR (0.60) TGM2F13A1LMNATGM1TGM3
SCHEMBL21787312 0.81 TGM2 (0.65) TGM2F13A1LMNATGM1TGM3
SCHEMBL28116067 0.80 TGM2 (0.58) TGM2F13A1LMNATGM1TGM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4828407-B2 — — 2011-11-30 — — JP claimed
EP-1594869-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF Targacept, Inc. (US) 2005-11-16 — — EP claimed
WO-2004076449-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF TARGACEPT, INC. (US) 2004-09-10 — — WO claimed
WO-2026103887-A1 PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 北京康辰药业股份有限公司 2026-05-21 — — WO disclosed
US-11840513-B2 Substituted nicotinimide inhibitors of BTK for treating cancer Guangzhou Innocare Pharma Tech Co., Ltd (CN) 2023-12-12 — — US disclosed
US-20220298153-A1 SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) 2022-09-22 — — US disclosed
EP-3426637-B1 COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE ANGEL PHARMACEUTICAL CO LTD (CN) 2022-02-09 — — EP disclosed
US-11149032-B2 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof ISOCURE BIOSCIENCES INC. (US) 2021-10-19 — — US disclosed
US-20200071309-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF ISOCURE BIOSCIENCES INC (US) 2020-03-05 — — US disclosed
US-20200062706-A1 LACTAM COMPOSTIONS CONOPCO INC DBA UNILEVER (US) 2020-02-27 — — US disclosed
US-10253019-B2 Tank-binding kinase inhibitor compounds GILEAD SCIENCES, INC. (US) 2019-04-09 — — US disclosed
US-10040781-B2 Tank-binding kinase inhibitor compounds GILEAD SCIENCES, INC. (US) 2018-08-07 — — US disclosed
EP-1594869-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF Targacept, Inc. (US) 2005-11-16 — — EP disclosed
WO-2004076449-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF TARGACEPT, INC. (US) 2004-09-10 — — WO disclosed
US-5500251-A (METH)ACRYLAMIDES AND MALEIMIDES AIR PRODUCTS AND CHEMICALS, INC. (US) 1996-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298153-A1 SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER BTK, SYK, LYN TGM2 2202/4885F13A1 3764/4885LMNA 3824/4885
US-10253019-B2 Tank-binding kinase inhibitor compounds TBKBP1, TNKS1BP1, TNKS TGM2 2177/4885F13A1 4444/4885LMNA 2240/4885
US-20200062706-A1 LACTAM COMPOSTIONS QPCT, AAAS, APH1A TGM2 110/4885F13A1 3061/4885LMNA 2114/4885
US-10040781-B2 Tank-binding kinase inhibitor compounds TBKBP1, TNKS1BP1, TNKS TGM2 2177/4885F13A1 4444/4885LMNA 2240/4885
US-11149032-B2 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof IDH1, IDH2, IDH3A TGM2 525/4885F13A1 3752/4885LMNA 2872/4885
US-20200071309-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF IDH1, IDH2, IDH3A TGM2 525/4885F13A1 3752/4885LMNA 2872/4885
US-11840513-B2 Substituted nicotinimide inhibitors of BTK for treating cancer BTK, SYK, LYN TGM2 2202/4885F13A1 3764/4885LMNA 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.